diphenylamine has been researched along with Neoplasms in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 19 (63.33) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Beijnen, JH; Bernards, R; de Vos, FYFL; Devriese, LA; Eskens, FALM; Huijberts, SCFA; Huitema, ADR; Lolkema, MPJK; Marchetti, S; Monkhorst, K; Opdam, FL; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM | 1 |
| Martin, DP; Mulder, N; Nkhoma, P; Sinkala, M | 1 |
| Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D | 1 |
| Alsina, M; Braña, I; Britten, CD; Del Conte, G; Ezeh, P; Houk, B; Kern, KA; Leong, S; Pathan, N; Pierce, KJ; Siu, LL; Soares, HP; Tabernero, J; Vermette, J; Wainberg, ZA | 1 |
| Chen, J; Huang, S; Wu, S; Wu, Y; Zeng, F | 1 |
| Chen, Y; Cui, G; Li, M; Meng, F; Yu, Z; Zhang, Y | 1 |
| Adjei, AA; Clendeninn, NJ; Dubowy, RL; Dy, GK; Eckhardt, SG; Gore, L; Iverson, C; Jeffers, M; Leffingwell, DP; Lewis, KD; Ma, WW; Miner, JN; Rajagopalan, P; Ramanathan, RK; Sheedy, B; Shen, Z; Von Hoff, DD; Weekes, CD; Weiss, GJ; Yeh, LT | 1 |
| Imoto, M; Kiga, M; Murakami, R; Nakanishi, T; Nakayama, A; Sasazawa, Y; Shikata, Y; Tashiro, E | 1 |
| Banerji, U; de Bono, JS; Stewart, A; Thavasu, P | 1 |
| Geisler, J; Hartung, IV; Hillig, RC; Hitchcock, M; Neuhaus, R; Pühler, F; Scholz, A; Siemeister, G; von Ahsen, O | 1 |
| Atrott, K; Cosin-Roger, J; Curioni-Fontecedro, A; Kiessling, MK; Lang, S; Rogler, G; Samaras, P; Scharl, M | 1 |
| Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT | 1 |
| Kiessling, MK; Rogler, G | 1 |
| Choisunirachon, N; Fujita, N; Hanafusa, M; Nakagawa, T; Nakaoka, N; Nishimura, R; Ong, SM; Saeki, K; Watanabe, M; Yoshitake, R | 1 |
| Sebolt-Leopold, JS | 1 |
| Garber, K | 1 |
| Appleby, T; Dadson, C; Hamatake, R; Iverson, C; Lai, C; Larson, G; Maderna, A; Miner, JN; Quart, B; Vernier, JM; Vo, T; Weingarten, P; Yeh, LT | 1 |
| Aliagas, I; Alvarado, R; Anderson, DJ; Belvin, M; Brandhuber, BJ; Friedman, LS; Gloor, SL; Hatzivassiliou, G; Hoeflich, KP; Jaiswal, BS; Koeppen, H; Liu, B; Ludlam, MJ; Malek, S; Morales, T; Seshagiri, S; Sideris, S; Song, K; Stokoe, D; Vigers, G; Yen, I | 1 |
| Bentivegna, S; Chapman, PB; DePrimo, SE; Krishnamurthi, SS; LoRusso, PM; Malburg, L; Nabell, LM; Ricart, AD; Rinehart, JJ; Tan, W; Wilner, KD | 1 |
| Brandner, S; Holmen, SL; Lastwika, KJ; McKinney, AJ; Robinson, JP; Vanbrocklin, MW | 1 |
| Akutagawa, JK; Braun, BS; Gorman, MF; Hong, WX; Lauchle, JO; Lyubynska, N; Shannon, K | 1 |
| Cho, HJ; Choi, HG; Kang, SH; Kim, CW; Kim, SH; Lee, S; Oh, YK; Shim, G | 1 |
| Brumby, AM; Humbert, PO; Manning, SA; Parisot, JP; Richardson, HE; Schlosser, T; Street, IP; Willoughby, LF | 1 |
| Hantani, Y; Kakegawa, J; Nakamura, M; Okajima, N; Sakai, T; Watanabe, Y; Yamaguchi, T; Yoshida, T | 1 |
| KATCHMAN, BJ; MURPHY, JP; ZIPF, RE | 1 |
| MELICHER, A | 1 |
| DURIS, I; DURISOVA, E; MARCINCIN, F; NIZNIK, V; RADAC, F | 1 |
| Lyons, J; Thompson, N | 1 |
| Espinoza, EO; Thornton, JI | 1 |
3 review(s) available for diphenylamine and Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Topics: Animals; Azetidines; Benzamides; Benzimidazoles; Diphenylamine; Genes, ras; GTP Phosphohydrolases; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Mutation; Neoplasms; Niacinamide; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Sulfonamides | 2015 |
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Topics: Animals; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2005 |
5 trial(s) available for diphenylamine and Neoplasms
| Article | Year |
|---|---|
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diphenylamine; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolinones | 2020 |
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Diphenylamine; Female; Humans; Irinotecan; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; TOR Serine-Threonine Kinases; Triazines | 2017 |
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cohort Studies; Diphenylamine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Staging; Neoplasms; Prognosis; Protein Kinase Inhibitors; Sulfonamides; Tissue Distribution; Young Adult | 2013 |
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diphenylamine; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2016 |
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Diphenylamine; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
22 other study(ies) available for diphenylamine and Neoplasms
| Article | Year |
|---|---|
Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies.
Topics: A549 Cells; Benzamides; Benzimidazoles; Cell Survival; Diphenylamine; Drug Evaluation, Preclinical; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mutation; Neoplasms; Transcription, Genetic | 2021 |
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
A turn-on fluorescence probe based on aggregation-induced emission for leucine aminopeptidase in living cells and tumor tissue.
Topics: Animals; Diphenylamine; Fluorescent Dyes; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Leucyl Aminopeptidase; Limit of Detection; Mice; Mice, Nude; Microscopy, Fluorescence; Nanostructures; Neoplasms; Optical Imaging; Spectrometry, Fluorescence; Stilbenes; Transplantation, Heterologous | 2018 |
Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid‑induced epithelial‑mesenchymal transition and stemness in HeLa, 5637 and SCC‑15 cells.
Topics: Benzamides; Dioxoles; Diphenylamine; Drug Synergism; Epithelial-Mesenchymal Transition; HeLa Cells; Humans; Neoplasms; Neoplastic Stem Cells; Pyridines; Pyrimidines; Valproic Acid | 2019 |
SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Butadienes; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasms; Nitriles; Protein Kinase Inhibitors; Sulfonamides; Transcription Factor 7-Like 2 Protein; Transcription, Genetic | 2015 |
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.
Topics: Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Diphenylamine; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; MAP Kinase Kinase 1; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Cells, Cultured | 2015 |
Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles.
Topics: Allosteric Regulation; Animals; Benzamides; Brain; Cell Line, Tumor; Cell Survival; Diphenylamine; Female; Half-Life; Humans; MAP Kinase Kinase 1; Mice; Mice, Nude; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Transplantation, Heterologous | 2015 |
Mutant HRAS as novel target for MEK and mTOR inhibitors.
Topics: Animals; Apoptosis; Benzamides; Benzimidazoles; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Diphenylamine; Humans; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cyclooxygenase Inhibitors; Dinoprostone; Diphenylamine; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Gene Expression Profiling; Neoplasms; Phenylacetates; Piroxicam; Prostaglandin D2 | 2017 |
Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.
Topics: Benzamides; Benzimidazoles; Diphenylamine; Drug Delivery Systems; Drug Design; Humans; MAP Kinase Signaling System; Models, Biological; Neoplasms; Protein Kinase Inhibitors; ras Proteins; Substrate Specificity | 2008 |
Trial offers early test case for personalized medicine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzimidazoles; Biomarkers, Tumor; Clinical Trials as Topic; Diphenylamine; Drug Approval; ErbB Receptors; Female; Humans; Mutation; Neoplasms; Proto-Oncogene Proteins B-raf; Receptor, ErbB-2; Signal Transduction; Trastuzumab; United States; United States Food and Drug Administration | 2009 |
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Topics: Administration, Oral; Allosteric Regulation; Animals; Cell Line, Tumor; Diphenylamine; Female; Half-Life; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Sulfonamides | 2009 |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Topics: Adenosine Triphosphate; Animals; Benzamides; Cell Line; Cell Membrane; Cell Proliferation; Diphenylamine; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indenes; Indoles; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrazoles; raf Kinases; ras Proteins; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Topics: Animals; Apoptosis; Benzamides; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Glioma; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines | 2011 |
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Topics: Animals; Benzamides; Cell Differentiation; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; GTP-Binding Proteins; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Mutation; Myeloproliferative Disorders; Myxovirus Resistance Proteins; Neoplasms; Proto-Oncogene Proteins p21(ras); raf Kinases; Random Allocation; Recombinant Fusion Proteins | 2011 |
Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.
Topics: Animals; Benzamides; Cations; Cell Line, Tumor; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Female; Gene Silencing; Genetic Therapy; Humans; Liposomes; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering | 2011 |
An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery.
Topics: Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Proliferation; Cytidine Triphosphate; Diphenylamine; Drosophila melanogaster; Drug Screening Assays, Antitumor; Glutamine; Isoxazoles; Neoplasms; Pharmacogenetics; Pilot Projects | 2013 |
Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Topics: Allosteric Regulation; Antineoplastic Agents; Benzamides; Butadienes; Chromatography, Affinity; Diphenylamine; Dose-Response Relationship, Drug; HEK293 Cells; HT29 Cells; Humans; Kinetics; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Nitriles; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction | 2012 |
A critical reevaluation of the diphenylamine test for malignancy.
Topics: Aniline Compounds; Diphenylamine; Humans; Neoplasms | 1961 |
[ASSESSMENT OF DIPHENYLAMINE-POSTIVE SUBSTANCE IN THE GASTRIC JUICE].
Topics: Achlorhydria; Anemia; Anemia, Pernicious; Biphenyl Compounds; Diphenylamine; Gastrectomy; Gastric Juice; Neoplasms; Stomach Neoplasms; Stomach Ulcer | 1963 |
[USE OF THE DIPHENYLAMINE REACTION IN THE DIAGNOSIS AND EXAMINATION OF STOMACH CANCER].
Topics: Biphenyl Compounds; Diphenylamine; Neoplasms; Stomach Neoplasms | 1963 |
Hazard of testing smokeless gunpowder with nitric acid.
Topics: Carcinogens; Diphenylamine; Humans; Medical Laboratory Personnel; Neoplasms; Nitrates; Nitric Acid; Nitrosamines; Occupational Diseases | 1992 |